Kaletra—from HIV to SARS to COVID-19 | 合法藥品大搜索

由 B Cao 著作 · 2020 · 被引用 4232 次 — In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Read More

由 PW Horby 著作 · 2020 · 被引用 121 次 — Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational ... Read More

2020年10月6日 — Lopinavir-ritonavir (Kaletra), a protease inhibitor mainly used for HIV, did not reduce mortality or speed recovery from COVID-19, Britain's large ... Read More

2020年7月10日 — — Inflammatory damage may increase GI absorption of the antiviral ... Bradycardia appeared to be a clinically significant risk of an HIV antiviral ... Read More

2021年2月11日 — Lopinavir/ritonavir and darunavir/cobicistat have been studied in patients with COVID-19. The clinical trials discussed below have not ... Read More

據新英格蘭醫學期刊的一項臨床試驗，在COVID-19的住院患者中，使用HIV治療藥物Lopinavir-Ritonavir並未加速恢復或降低死亡率。這項研究中，199 ... Read More

由 SR Hosein 著作 — Kaletra—from HIV to SARS to COVID-19. One of the medicines that has been undergoing extensive testing in people with COVID-19 is a fixed-dose formulation ... Read More

The NIH Panel for COVID-19 Treatment Guidelines recommend against the use of lopinavir/ritonavir or other HIV protease inhibitors, owing to unfavorable ... Read More

2021年4月22日 — A randomized, controlled trial of 685 adult COVID-19 outpatients in Brazil ... lopinavir-ritonavir significantly lowered rates of coronavirus–related ... Read More